{"id":187,"date":"2026-06-02T09:00:00","date_gmt":"2026-06-02T09:00:00","guid":{"rendered":"https:\/\/arenasignals.com\/?p=187"},"modified":"2026-10-08T01:41:34","modified_gmt":"2026-10-08T01:41:34","slug":"neuronetics-new-real-world-neurostar-data-presented-at-the-clinical-tms-society-meeting","status":"publish","type":"post","link":"https:\/\/arenasignals.com\/?p=187","title":{"rendered":"Neuronetics: New real-world NeuroStar data presented at the Clinical TMS Society meeting"},"content":{"rendered":"
\n
Signal strength<\/strong> \u00b7 Clinical evidence<\/span>\u2605\u2605\u2605\u2605\u2606<\/span><\/div>\n
\n

Arena Signals interpretation<\/h2>\n

The expanding evidence base can support physician adoption, payer discussions and broader treatment protocols. The adolescent and maintenance-treatment findings could also expand the long-term commercial opportunity.<\/p>\n<\/section>\n

\n

News summary<\/h2>\n

New real-world NeuroStar data presented at the Clinical TMS Society meeting.<\/p>\n<\/section>\n

<\/p>\n

\n

Full company announcement<\/h2>\n
\n

MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar\u00ae Advanced Therapy, today announced its participation as a Silver Sponsor at the 2026 Clinical TMS Society (CTMSS) Annual Meeting, where real-world data from the Company\u2019s proprietary TrakStar database will be featured in an oral presentation and multiple scientific posters focused on advancing the understanding of transcranial magnetic stimulation (TMS) for mental health conditions.\u00a0<\/p>\n

NeuroStar-related presentations at CTMSS reflect the Company\u2019s commitment to advancing TMS research and learning from real-world evidence. The Company continues to explore treatment outcomes across diverse patient populations in real-world clinical settings.<\/p>\n

\u201cThe continued expansion of real-world evidence is critical to advancing our understanding of TMS and its role in clinical practice,\u201d said Cory Anderson, Chief Technology Officer at Neuronetics. \u201cThese findings reflect the value of combining the industry\u2019s largest real-world TMS database with rigorous scientific analysis to generate meaningful insights that can be shared with the broader mental health community during CTMSS.\u201d<\/p>\n

The following data will be presented:<\/p>\n

The Effectiveness of Transcranial Magnetic Stimulation for Major Depressive Disorder: Associations with Age and Biological Sex<\/strong><\/p>\n